Gloria Lee

Biography

Dr. Lee’s career in oncology drug development spans over 24 years in big pharma and biotech settings. She has brought products from early clinical development to marketing approval. Most recently, she was Chief Medical Officer at Beyondspring Pharmaceuticals, Inc., and EVP, Clinical & Medical Affairs at Delcath Systems. She was the first CMO at Kite Pharma, the immuno-oncology company. Her past accomplishments included the Taxotere NDA at Rhone-Poulenc Rorer (now Sanofi) and registration-enabling clinical development of Zytiga (abiraterone) at Cougar Biotechnology (now Johnson & Johnson). Her other projects included ibandronate at Hoffmann-La Roche, tezacitabine at Chiron (now Novartis), entinostat at Syndax Pharmaceuticals, GM-CSF at Sandoz (now Novartis), p53 gene therapy at Rhone-Poulenc Rorer Gencell, and various early-phase projects in biologics and immunotherapy. Dr. Lee received her Ph.D. from Columbia University and M.D. from the University of Miami. Her internal medicine residency was at Georgetown University Hospital, and Hematology-Oncology fellowship at Fox Chase Cancer Center.

Research Interest

pharmaceutical